N-Acetyltransferase 2 Genotype-Related Sulfapyridine Acetylation and Its Adverse Events
スポンサーリンク
概要
- 論文の詳細を見る
Sulfapyridine(SP), one of the metabolites of sulfasalazine(SASP), is further metabolized into N-acetylsulfapyridine (AcSP) by polymorphic N-acetyltransferase 2 (NAT2). NAT2 activity has been diagnosed by phenotyping, that is, evaluating plasma concentrations or urinary excretions of tentatively administered test drugs for dose individualization and avoidance of serious adverse events. Herein, we investigated the relationship between NAT2 genotypes and the pharmacokinetics of SP in healthy Japanese subjects, as well as the adverse events of SASP in patients with inflammatory bowel disease (IBD). Eight healthy subjects and 13 IRD patients were classified into three groups by NAT2 genotyping; the homozygote for the wild-type allele (Rapid Types), the compound heterozygote for the wild-type and mutant alleles (Intermediate Types), and the homozygote for mutant alleles (Slow Types). A single oral dose of 40 mg/kg SASP was administered to each healthy subject, and plasma and urine samples were taken until 51 and 72 h after administration, respectively. Both the SP and AcSP concentrations in each sample were determined by the HPLC method. The NAT2 genotypes were well-correlated with the plasma concentrations or urinary excretions of SP and AcSP in 8 healthy subjects, except for one Slow Type. In patients with IBD, skin rash was seen in 3 of 6 Rapid Types and 1 of 6 Intermediate Types, consistent with the concept that hypersensitive reactions are independent of serum SP concentrations. In contrast, SASP dosing-related acute pancreatitis was found in the Slow Type patient. In this case, the NAT2 activity was diagnosed by genotyping in advance, and the medical staff could pay scrupulous attention, resulting in no serious subjective symptoms such as abdominal pain, anorexia or fever. Further investigations on the relationship between the NAT2 genotype and adverse events are required, although genotyping appeared to be a promising method to avoid such serious adverse events.
- 公益社団法人日本薬学会の論文
- 2002-08-01
著者
-
Nakamura T
Department Of Gastroenterological Surgery Kobe University Graduate School Of Medical Sciences
-
谷川原 祐介
慶応義塾大学薬剤部
-
OKUMURA Katsuhiko
Department of Hospital Pharmacy, Kobe University School of Medicine
-
SAKAEDA Toshiyuki
Department of Hospital Pharmacy, Kobe University School of Medicine
-
Kasuga Masato
Department Of Hospital Pharmacy School Of Medicine Kobe University
-
KASUGA Masato
Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Kobe University
-
Kakumoto M
Department Of Hospital Pharmacy School Of Medicine Kobe University
-
Kimura T
Kobe University Graduate School Of Medicine
-
Takara Kohji
Department of Hospital Pharmacy, Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University
-
KITA Tomoko
Department of Hospital Pharmacy, School of Medicine, Kobe University
-
AOYAMA Nobuo
Department of Endoscopy, School of Medicine, Kobe University
-
Okumura K
Department Of Clinical Evaluation Of Pharmacotherapy Kobe University Graduate School Of Medicine
-
Aoyama Nobuo
Department Of Endoscopy School Of Medicine Kobe University
-
Aoyama Nobuo
Department Of Endoscopy And Division Of Diabetes Digestive And Kidney Diseases Department Of Clinica
-
Takara Kohji
Department Of Hospital Pharmacy Faculty Of Pharmaceutical Sciences Kyoto Pharmaceutical University
-
Takara Kohji
Department Of Hospital Pharmacy School Of Medicine Kobe University
-
TANIGAWA Yusuke
Department of Hospital Pharmacy School of Medicine, Keio University
-
Sakaeda Toshiyuki
Department Of Hospital Pharmacy Kobe University Hospital
-
SAKAI Toshiyuki
Division of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefect
-
KOMADA Fusao
Department of Drug Informatics, Faculty of Pharmaceutical Sciences, Josai University
-
Kita T
Institute Of Natural Science Kobe University
-
Shirakawa T
Kobe University School Of Medicine
-
Kamiyama Fumio
京都大学再生医科学研究所
-
Kodama Fusao
Cosmed Pharmaceutical Co. Ltd.
-
Tanigawara Yusuke
Department Of Clinical Pharmacokinetics And Pharmacodynamics School Of Medicine Keio University
-
Kita Tomoko
Department Of Applied Physics Osaka University
-
Okumura Katsuhiko
Department Of Hospital Pharmacy School Of Medicine Kobe University
-
HATANAKA Hisakatsu
Hyogo Prefectural Institute of Public Health
-
GOBARA Manabu
Department of Hospital Pharmacy, School of Medicine, Kobe University
-
Okumura Katsuhiko
Department Of Clinical Evaluation Of Pharmacotherapy Kobe University Graduate School Of Medicine
-
Okumura Katsuhiko
Department Of Hospital Pharmacy Kyoto Pharmaceutical University:department Of Hospital Pharmacy Kobe
-
Hatanaka Hisakatsu
Hyogo Prefrctural Institute Of Public Health
-
Kasuga Masato
Division Of Diabetes And Digestive And Kidney Diseases Department Of Clinical Molecular Medicine Kob
-
Komada F
Department Of Pharmacy Kobe University School Of Medicine
-
Nakamura Takeshi
Department Of Gastroenterological Surgery Kobe University Graduate School Of Medical Sciences
-
Sakai T
Department Of Internal Medicine And Gastrointestinal Endoscopy Saga Medical School
-
Gobara Manabu
Department Of Hospital Pharmacy School Of Medicine Kobe University
-
Aoyama Nobuo
Second Department Of Internal Medicine Kobe University School Of Medicine
-
Koishi Tomokazu
Department Of Hospital Pharmacy Faculty Of Pharmaceutical Sciences Kyoto Pharmaceutical University
-
Sakai Toshiyuki
Division Of Molecular-targeting Cancer Prevention Graduate School Of Medical Science Kyoto Prefectur
-
Tanigawa Yusuke
Department Of Hospital Pharmacy School Of Medicine Keio University
-
Tanigawa Yusuke
Department Of Chemical Engineering And Materials Science Faculty Of Science And Engineering Doshisha University
-
Kaneko M
Department Of Pharmacology Faculty Of Pharmaceutical Sciences Chiba Institute Of Science
-
Kaneko Masayuki
千葉科学大学
関連論文
- Levofloxacin 500mg 経口投与時の母集団薬物動態/薬力学解析
- 呼吸器感染症に対する sitafloxacin の一般臨床試験
- 慢性呼吸器病変の二次感染患者を対象とした garenoxacin の臨床第III相試験 : PK/PD試験
- MRSA感染症患者に対する arbekacin 200mg 1日1回投与の治療効果 : 臨床薬理試験
- P-124 未治療進行非小細胞肺癌に対するCBDCA+DOC併用療法の検討(化学療法2,第49回日本肺癌学会総会号)
- 5.連日透析により化学療法に伴う重篤な副作用を回避しえた非小細胞肺癌透析患者の1例(第150回日本肺癌学会関東支部会,関東支部,支部活動)
- K1-42 UGT1A1遺伝子多型とイリノテカンの有害事象およびグルクロン酸抱合能に関するゲノム薬理学的検討(高得点演題7 腫瘍,高得点演題プログラム,第61回日本産科婦人科学会学術講演会)
- 高齢者におけるfaropenem sodiumの体内動態ならびに安全性の検討
- 抗原提示細胞指向型キャリアを用いたNFκBデコイ送達に基づくラット心移植急性拒絶におけるサイトカイン産生抑制
- K4-3 塩酸イリノテカンの副作用軽減を目指したUGTIA1遺伝子多型解析(高得点婦人科腫瘍学7,高得点演題プログラム,第60回日本産科婦人科学会学術講演会)
- O-2-222 成人生体肝移植における代謝拮抗剤の有用性について,特にミゾリビンについての検討(肝 移植2,一般演題(口演),第62回日本消化器外科学会定期学術総会)
- 薬剤の調剤における安全対策 (特集 医薬品のリスクマネージメント)
- 小児深在性真菌症患者における micafungin の有効性, 安全性および薬物動態
- 小児科領域感染症における meropenem の臨床的検討
- アルベカシンのPK/PD解析 : MRSA患者に対する臨床効果および副作用発現に関与する薬物動態値と要因の多変量解析
- 本邦における抗MRSA薬 arbekacin を中心とした使用実態
- P-500 骨肉腫患者におけるメトトレキサートの体内動態におよぼすプロトンポンプ阻害剤・ラベプラゾールナトリウムの影響(7.薬物相互作用・(基礎と臨床),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
- 血液透析患者におけるテイコプラニンの至適投与法の検討
- P-012 プロテインチップを用いた小腸移植における拒絶マーカーの探索とその臨床応用 : MRP-8/14ならびにリゾチームについて(ポスター 臓器移植1,Better Life for Sick Children, Better Future for Pediatric Surgery,第45回日本小児外科学会学術集会)
- 多発性骨髄腫患者におけるサリドマイドの体内動態と薬効および副作用の関係解析
- 28-02-05 多発性骨髄腫患者におけるサリドマイド療法への薬剤師の関与 : 血中濃度モニタリングと薬品管理体制の確立
- 抗MRSA薬のTDMに関する全国アンケート調査
- Vancomycin の Therapeutic drug monitoring (TDM) 実施に関する抗菌化学療法認定薬剤師制度認定委員会ならびに抗菌薬TDM標準化ワーキングの見解
- SP14-1 日本病院薬剤師会によるがん専門薬剤師認定制度の取り組み(SP14「がん専門薬剤師養成への取り組みと今後の課題」,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
- P-195 階層化医薬品情報(e 添付文書情報)作成とハイライト情報の携帯電話・携帯情報端末での利用の試み
- Association of Cumulative Cyclosporine Dose with Its Irreversible Nephrotoxicity in Japanese Patients with Pediatric-Onset Autoimmune Diseases(Biopharmacy)
- Prediction of systemic exposure to cyclosporine in Japanese pediatric patients
- 薬理遺伝とオーダーメイド医療--とくに小児の薬物療法との関連 (日常診療に役立つ最新の薬物治療と副作用対策) -- (総論)
- 抗生物質併用投与による漢方薬配糖体成分の体内動態変動とその対策
- 新しい腎機能マーカー・血清シスタチンC濃度を用いた腎排泄型薬物投与設計の有用性
- P-444 腎排泄型薬物の投与設計における新しい腎機能マーカー・血清シスタチン C 濃度の有用性
- O-30 生体部分肝移植後の肝機能および薬物代謝能の推移とシクロスポリン体内動態との関係解析
- 巻頭言
- Long-term outcome of severe acute pancreatitis
- Prediction of early death in severe acute pancreatitis
- Role of Toll-Like Receptor 4 in the Pathophysiology of Severe Acute Pancreatitis in Mice
- Decreased Expression of Toll-like Receptor 2 and 4 on Macrophages in Experimental Severe Acute Pancreatitis
- Treatment outcome of selective digestive decontamination and enteral nutrition in patients with severe acute pancreatitis
- Treatment strategy against infection : clinical outcome of continuous regional arterial infusion, enteral nutrition, and surgery in severe acute pancreatitis
- Immunosuppression in patients with severe acute pancreatitis
- Elevation of plasma tissue factor levels in patients with severe acute pancreatitis
- Correlation between expression of major histocompatibility complex class I and that of antigen presenting machineries in carcinoma cell lines of the pancreas, biliary tract and colon
- Reversal Effects of Ca2+ Antagonists on Multidrug Resistance via Down-regulation of MDR1 mRNA
- Three-Dimensional, but not Two-Dimensional, Culture Results in Tumor Growth Enhancement after Exposure to Anticancer Drugs
- Knock-down of Sorcin Induces Up-regulation of MDR1 in HeLa Cells(Molecular and Cell Biology)
- Effects of Reactive Oxygen Species on Cell Proliferation and Death in HeLa Cells and Its MDR1-Overexpressing Derivative Cell Line
- Effects of carvedilol on MDR1-mediated multidrug resistance : comparison with verapamil
- Effects of St John's Wort and Hypericin on Cytotoxicity of Anticancer Drugs
- Cytotoxic Effects of 27 Anticancer Drugs in HeLa and MDR1-Overexpressing Derivative Cell Lines
- Antiproliferative Activity of Rhinacanthus nasutus (L.) KURZ Extracts and the Active Moiety, Rhinacanthin C(Pharmacology)
- MDR1 T-129C Polymorphism can be Predictive of Differentiation, and Thereby Prognosis of Colorectal Adenocarcinomas in Japanese(Biopharmacy)
- MDR1, MRP1 and MRP2 Genotypes and In Vitro Chemosensitivity in Japanese Patients with Colorectal Adenocarcinomas
- Intradermal Concentration of Hydroquinone after Application of Hydroquinone Ointments Is Higher than Its Cytotoxic Concentration(Biopharmacy)
- Different Contribution of CYP2C19 in the in Vitro Metabolism of Three Proton Pump Inhibitors
- A Multi-institutional Study on Adjuvant Chemotherapy for the Prevention of Post-operative Liver Metastases in Colorectal Cancer Patients : Comparison Between Hepatic Arterial and Portal Adriamycin Plus Oral UFT Administration
- MDR1 Haplotype Frequencies in Japanese and Caucasian, and in Japanese Patients with Colorectal Cancer and Esophageal Cancer
- MDR1 C3435T Polymorphism Is Predictive of Later Onset of Ulcerative Colitis in Japanese(Biopharmacy)
- Reversal Effects of Antifungal Drugs on Multidrug Resistance in MDR1-Overexpressing HeLa Cells
- P-371 網膜硝子体手術症例における抗炎症薬・フルルビプロフェンアキセチルの先制鎮痛効果(1.薬物療法(基礎と臨床),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
- 中央手術室内サテライトファーマシーの設置と常駐薬剤師による医薬品の一元管理
- P-697 手術部におけるサテライトファーマシーの有用性とその評価 : 常駐薬剤師による4年間の活動を通して(13.薬品管理、使用状况調査2,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
- 脂肪乳剤併用による酒石酸ビノレルビン静脈炎軽減効果に関する研究
- ワルファリン (特集 小児疾患における臨床遺伝学の進歩) -- (遺伝子診断がもたらす治療の進歩)
- SP11-2 プロテオミクス技術を活用した小腸移植後の急性拒絶マーカーおよび免疫抑制剤の薬効マーカーの開発(SP11「移植医療とTDM」,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
- 抗菌薬のPK/PDとTDMの意義
- SP15-3 薬剤師が常駐する病棟サテライトファーマシーの取り組み : 病棟常駐の利点を活かした業務展開(SP15「注射薬調剤と危機管理」,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
- 手術室における薬剤業務の取り組み (特集 院内で広がる薬剤師機能--薬剤業務の新たな課題)
- IL-1β Genotype-Related Effect of Prednisolone on IL-1β Production in Human Peripheral Blood Mononuclear Cells under Acute Inflammation(Pharmacology)
- Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma
- Effect of Therapeutic Moderate Hypothermia on Multi-drug Resistance Protein 1-Mediated Transepithelial Transport of Drugs
- 急性炎症下におけるヒト末梢血単核球MDR1の遺伝子型に依存した遺伝子発現量ならびに機能低下
- Comparison of Synthetic DNA Templates with Authentic cDNA Templates in Terms of Quantification by Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction(Analytical Biochemistry)
- Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport
- 電流検出方式DNAチップを用いた複数遺伝子型同時判定法のMDR1遺伝子への応用
- Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma : Prognostic factors and unique toxicity profile
- O-54 漢方薬配糖体成分の吸収におよぼす抗生物質併用投与の影響
- Effects of Polymorphisms of MDR1, MRP1, and MRP2 Genes on Their mRNA Expression Levels in Duodenal Enterocytes of Healthy Japanese Subjects(Biopharmacy)
- MDR1-Mediated Interaction of Digoxin with Antiarrhythmic or Antianginal Drugs
- Factors Influencing the Prediction of Steady State Concentrations of Digoxin
- Interaction of Docetaxel ("Taxotere") with Human P-Glycoprotein
- MICROMEDEX Healthcare Series (特集 データベース)
- 患者のQOL向上と薬剤師の関わり PART 2. 服薬指導と病棟活動(44)階層化添付文書情報(e添付文書)による医薬品適正使用の推進
- 薬剤師の業務に役立つインターネットサイト
- 知っていると便利なホームページ(34)ウェブページ翻訳
- 知っていると便利なホームページ(26)National Guideline Clearinghouse
- 個別化治療の可能性 (がん薬物療法学--基礎・臨床研究のアップデート) -- (抗悪性腫瘍薬の薬理学・薬力学・薬理遺伝学)
- PK/PDバイオマーカーに基づく抗がん剤治療の個別化 (特集 非選択的治療から選択的治療へのパラダイムシフト(2))
- P-gp誘導 Caco-2 細胞 : P-gp高感度 Assay System の構築
- N-Acetyltransferase2 Genotype Correlated with Isoniazid Acetylation in Japanese Tuberculous Patients
- Effects of Various Storage Conditions and Alterations of Antioxidant Contents on Chromatic Aberration of Hydroquinone Ointment(Biopharmacy)
- Effect of Serum Triglyceride Concentration on the Fluctuation of Whole Blood Concentration of Cyclosporin A in Patients
- Proapoptotic Effect of a Dietary Supplement : Water Soluble Chitosan Activates Caspase-8 and Modulating Death Receptor Expression
- N-Acetyltransferase 2 Genotype-Related Sulfapyridine Acetylation and Its Adverse Events
- Optimal Dose of Omeprazole for CYP2C19 Extensive Metabolizers in Anti-Helicobacter pylori Therapy : Pharmacokinetic Considerations
- N-Acetyltransferase 2 Genotype Correlates with Sulfasarazine Pharmacokinetics after Multiple Dosing in Healthy Japanese Subjects
- Pharmaceutical and Clinical Assessment of Hydroquinone Ointment Prepared by Extemporaneous Nonsterile Compounding
- Molecular and Pharmacokinetic Properties of 222 Commercially Available Oral Drugs in Humans
- The Novel Anticancer Drug KRN5500 Interacts with, but is Hardly Transported by, Human P-Glycoprotein
- バルプロ酸誘発高アンモニア血症に対するCPS1 4217C>A遺伝子多型の影響
- MDR1 Genotype-Related Pharmacokinetics and Pharmacodynamics